{
  "metadata": {
    "description": "Biotech partnership and licensing deal data",
    "source": "SEC filings, press releases, company investor relations",
    "last_updated": "2026-01-26",
    "version": "1.0.0"
  },
  "partnerships": [
    {
      "ticker": "MRNA",
      "partner_name": "Merck",
      "deal_type": "co_development",
      "announcement_date": "2023-10-02",
      "upfront_payment": 250,
      "total_potential_value": 1800,
      "indication": "oncology",
      "asset_name": "mRNA-4157/V940",
      "is_active": true,
      "notes": "Individualized neoantigen therapy (INT) for melanoma"
    },
    {
      "ticker": "MRNA",
      "partner_name": "Vertex",
      "deal_type": "collaboration",
      "announcement_date": "2023-06-15",
      "upfront_payment": 75,
      "total_potential_value": 600,
      "indication": "cystic fibrosis",
      "asset_name": "mRNA gene editing",
      "is_active": true
    },
    {
      "ticker": "ALNY",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-02-28",
      "upfront_payment": 310,
      "total_potential_value": 2200,
      "indication": "neurology",
      "asset_name": "ALN-APP",
      "is_active": true,
      "notes": "Alzheimer's disease program"
    },
    {
      "ticker": "ALNY",
      "partner_name": "Regeneron",
      "deal_type": "co_development",
      "announcement_date": "2019-04-08",
      "upfront_payment": 800,
      "total_potential_value": 2500,
      "indication": "multiple",
      "asset_name": "RNAi platform",
      "is_active": true
    },
    {
      "ticker": "BEAM",
      "partner_name": "Pfizer",
      "deal_type": "co_development",
      "announcement_date": "2022-01-10",
      "upfront_payment": 300,
      "total_potential_value": 1350,
      "indication": "rare disease",
      "asset_name": "Base editing programs",
      "is_active": true
    },
    {
      "ticker": "BEAM",
      "partner_name": "Eli Lilly",
      "deal_type": "collaboration",
      "announcement_date": "2023-07-19",
      "upfront_payment": 200,
      "total_potential_value": 800,
      "indication": "multiple",
      "asset_name": "Base editing liver targets",
      "is_active": true
    },
    {
      "ticker": "CRSP",
      "partner_name": "Vertex",
      "deal_type": "co_development",
      "announcement_date": "2015-10-26",
      "upfront_payment": 75,
      "total_potential_value": 2600,
      "indication": "sickle cell disease",
      "asset_name": "CTX001/exa-cel",
      "is_active": true,
      "notes": "Led to Casgevy approval"
    },
    {
      "ticker": "CRSP",
      "partner_name": "Regeneron",
      "deal_type": "research_collaboration",
      "announcement_date": "2021-06-22",
      "upfront_payment": 50,
      "total_potential_value": 350,
      "indication": "multiple",
      "asset_name": "In vivo gene editing",
      "is_active": true
    },
    {
      "ticker": "EDIT",
      "partner_name": "Bristol-Myers Squibb",
      "deal_type": "option_agreement",
      "announcement_date": "2023-02-15",
      "upfront_payment": 50,
      "total_potential_value": 180,
      "indication": "oncology",
      "asset_name": "Engineered cell therapies",
      "is_active": true
    },
    {
      "ticker": "NTLA",
      "partner_name": "Regeneron",
      "deal_type": "co_development",
      "announcement_date": "2016-04-18",
      "upfront_payment": 75,
      "total_potential_value": 1000,
      "indication": "multiple",
      "asset_name": "CRISPR/Cas9 platform",
      "is_active": true
    },
    {
      "ticker": "IONS",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-01-08",
      "upfront_payment": 200,
      "total_potential_value": 1500,
      "indication": "neurology",
      "asset_name": "ION363/tominersen",
      "is_active": true
    },
    {
      "ticker": "IONS",
      "partner_name": "Biogen",
      "deal_type": "collaboration",
      "announcement_date": "2018-06-14",
      "upfront_payment": 1000,
      "total_potential_value": 2500,
      "indication": "neurology",
      "asset_name": "Antisense platform",
      "is_active": true,
      "notes": "Long-standing partnership - Spinraza, etc."
    },
    {
      "ticker": "IONS",
      "partner_name": "AstraZeneca",
      "deal_type": "exclusive_license",
      "announcement_date": "2020-11-02",
      "upfront_payment": 100,
      "total_potential_value": 950,
      "indication": "cardiovascular",
      "asset_name": "AKCEA-APO-LRx",
      "is_active": true
    },
    {
      "ticker": "SGEN",
      "partner_name": "Pfizer",
      "deal_type": "acquisition_option",
      "announcement_date": "2023-03-13",
      "upfront_payment": 43000,
      "total_potential_value": 43000,
      "indication": "oncology",
      "asset_name": "Full company",
      "is_active": false,
      "notes": "Acquired by Pfizer"
    },
    {
      "ticker": "BMRN",
      "partner_name": "Sarepta",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-06-10",
      "upfront_payment": 170,
      "total_potential_value": 750,
      "indication": "rare disease",
      "asset_name": "Gene therapy co-promotion",
      "is_active": true
    },
    {
      "ticker": "SRPT",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2019-12-23",
      "upfront_payment": 1150,
      "total_potential_value": 4300,
      "indication": "muscular dystrophy",
      "asset_name": "SRP-9001 (ex-US)",
      "is_active": true
    },
    {
      "ticker": "VRTX",
      "partner_name": "CRISPR Therapeutics",
      "deal_type": "co_development",
      "announcement_date": "2015-10-26",
      "upfront_payment": 75,
      "total_potential_value": 2600,
      "indication": "sickle cell disease",
      "asset_name": "CTX001/exa-cel",
      "is_active": true
    },
    {
      "ticker": "VRTX",
      "partner_name": "Moderna",
      "deal_type": "collaboration",
      "announcement_date": "2023-06-15",
      "upfront_payment": 75,
      "total_potential_value": 600,
      "indication": "cystic fibrosis",
      "asset_name": "mRNA gene editing",
      "is_active": true
    },
    {
      "ticker": "INCY",
      "partner_name": "Eli Lilly",
      "deal_type": "co_development",
      "announcement_date": "2009-12-17",
      "upfront_payment": 90,
      "total_potential_value": 680,
      "indication": "autoimmune",
      "asset_name": "Baricitinib",
      "is_active": true,
      "notes": "JAK inhibitor collaboration"
    },
    {
      "ticker": "INCY",
      "partner_name": "Novartis",
      "deal_type": "exclusive_license",
      "announcement_date": "2009-11-24",
      "upfront_payment": 150,
      "total_potential_value": 1100,
      "indication": "oncology",
      "asset_name": "Ruxolitinib (ex-US)",
      "is_active": true
    },
    {
      "ticker": "BLUE",
      "partner_name": "Bristol-Myers Squibb",
      "deal_type": "exclusive_license",
      "announcement_date": "2018-02-28",
      "upfront_payment": 200,
      "total_potential_value": 500,
      "indication": "oncology",
      "asset_name": "bb2121/ide-cel",
      "is_active": false,
      "notes": "2seventy bio spinoff"
    },
    {
      "ticker": "NVAX",
      "partner_name": "Sanofi",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-05-10",
      "upfront_payment": 500,
      "total_potential_value": 1500,
      "indication": "infectious disease",
      "asset_name": "COVID-19 vaccine",
      "is_active": true,
      "notes": "Co-exclusive license for COVID vaccines"
    },
    {
      "ticker": "BNTX",
      "partner_name": "Pfizer",
      "deal_type": "co_development",
      "announcement_date": "2020-03-17",
      "upfront_payment": 185,
      "total_potential_value": 10000,
      "indication": "infectious disease",
      "asset_name": "BNT162b2/Comirnaty",
      "is_active": true,
      "notes": "COVID-19 vaccine collaboration"
    },
    {
      "ticker": "BNTX",
      "partner_name": "Regeneron",
      "deal_type": "research_collaboration",
      "announcement_date": "2022-09-06",
      "upfront_payment": 50,
      "total_potential_value": 400,
      "indication": "oncology",
      "asset_name": "FixVac cancer vaccines",
      "is_active": true
    },
    {
      "ticker": "ARWR",
      "partner_name": "Janssen",
      "deal_type": "exclusive_license",
      "announcement_date": "2018-10-03",
      "upfront_payment": 175,
      "total_potential_value": 3500,
      "indication": "hepatology",
      "asset_name": "HBV RNAi",
      "is_active": true
    },
    {
      "ticker": "ARWR",
      "partner_name": "Takeda",
      "deal_type": "exclusive_license",
      "announcement_date": "2021-05-10",
      "upfront_payment": 300,
      "total_potential_value": 1100,
      "indication": "rare disease",
      "asset_name": "ARO-AAT",
      "is_active": true
    },
    {
      "ticker": "SNDX",
      "partner_name": "Incyte",
      "deal_type": "co_development",
      "announcement_date": "2024-09-16",
      "upfront_payment": 75,
      "total_potential_value": 700,
      "indication": "oncology",
      "asset_name": "Menin inhibitors",
      "is_active": true
    },
    {
      "ticker": "GILD",
      "partner_name": "Arcus Biosciences",
      "deal_type": "co_development",
      "announcement_date": "2020-05-27",
      "upfront_payment": 175,
      "total_potential_value": 1600,
      "indication": "oncology",
      "asset_name": "Multiple I/O programs",
      "is_active": true
    },
    {
      "ticker": "GILD",
      "partner_name": "Galapagos",
      "deal_type": "exclusive_license",
      "announcement_date": "2019-07-14",
      "upfront_payment": 3950,
      "total_potential_value": 5100,
      "indication": "autoimmune",
      "asset_name": "Filgotinib and pipeline",
      "is_active": true
    },
    {
      "ticker": "RCKT",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2023-03-06",
      "upfront_payment": 110,
      "total_potential_value": 2700,
      "indication": "rare disease",
      "asset_name": "Danon disease program",
      "is_active": true
    },
    {
      "ticker": "ADPT",
      "partner_name": "Genentech",
      "deal_type": "co_development",
      "announcement_date": "2018-12-21",
      "upfront_payment": 300,
      "total_potential_value": 1800,
      "indication": "oncology",
      "asset_name": "Neoantigen programs",
      "is_active": true
    },
    {
      "ticker": "KYMR",
      "partner_name": "Sanofi",
      "deal_type": "collaboration",
      "announcement_date": "2020-07-13",
      "upfront_payment": 150,
      "total_potential_value": 2000,
      "indication": "multiple",
      "asset_name": "Protein degrader platform",
      "is_active": true
    },
    {
      "ticker": "KYMR",
      "partner_name": "Vertex",
      "deal_type": "collaboration",
      "announcement_date": "2023-04-03",
      "upfront_payment": 100,
      "total_potential_value": 500,
      "indication": "multiple",
      "asset_name": "Targeted protein degradation",
      "is_active": true
    },
    {
      "ticker": "LEGN",
      "partner_name": "Janssen",
      "deal_type": "exclusive_license",
      "announcement_date": "2017-12-21",
      "upfront_payment": 350,
      "total_potential_value": 1200,
      "indication": "oncology",
      "asset_name": "BCMA CAR-T",
      "is_active": true,
      "notes": "Carvykti (ciltacabtagene)"
    },
    {
      "ticker": "LEGN",
      "partner_name": "Novartis",
      "deal_type": "option_agreement",
      "announcement_date": "2022-08-29",
      "upfront_payment": 50,
      "total_potential_value": 500,
      "indication": "oncology",
      "asset_name": "DLL3/CD3 bispecific",
      "is_active": true
    },
    {
      "ticker": "FOLD",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2017-08-07",
      "upfront_payment": 30,
      "total_potential_value": 200,
      "indication": "rare disease",
      "asset_name": "AT-GAA",
      "is_active": true
    },
    {
      "ticker": "RARE",
      "partner_name": "Alexion",
      "deal_type": "co_development",
      "announcement_date": "2018-06-04",
      "upfront_payment": 40,
      "total_potential_value": 400,
      "indication": "rare disease",
      "asset_name": "Next-gen C5 inhibitor",
      "is_active": true
    },
    {
      "ticker": "RCUS",
      "partner_name": "Gilead",
      "deal_type": "co_development",
      "announcement_date": "2020-05-27",
      "upfront_payment": 175,
      "total_potential_value": 1600,
      "indication": "oncology",
      "asset_name": "Multiple I/O programs",
      "is_active": true
    },
    {
      "ticker": "APLS",
      "partner_name": "Swedish Orphan Biovitrum",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-04-22",
      "upfront_payment": 250,
      "total_potential_value": 1000,
      "indication": "rare disease",
      "asset_name": "Systemic pegcetacoplan",
      "is_active": true
    },
    {
      "ticker": "CYTK",
      "partner_name": "Novartis",
      "deal_type": "exclusive_license",
      "announcement_date": "2023-08-21",
      "upfront_payment": 55,
      "total_potential_value": 350,
      "indication": "autoimmune",
      "asset_name": "CK-3773274",
      "is_active": true
    },
    {
      "ticker": "DNLI",
      "partner_name": "Biogen",
      "deal_type": "co_development",
      "announcement_date": "2020-08-24",
      "upfront_payment": 560,
      "total_potential_value": 2200,
      "indication": "neurology",
      "asset_name": "Anti-TDP43 program",
      "is_active": true
    },
    {
      "ticker": "PCVX",
      "partner_name": "Merck",
      "deal_type": "exclusive_license",
      "announcement_date": "2023-11-28",
      "upfront_payment": 150,
      "total_potential_value": 1200,
      "indication": "infectious disease",
      "asset_name": "VAX-24",
      "is_active": true
    },
    {
      "ticker": "IMVT",
      "partner_name": "Roche",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-03-18",
      "upfront_payment": 80,
      "total_potential_value": 720,
      "indication": "autoimmune",
      "asset_name": "Batoclimab",
      "is_active": true
    },
    {
      "ticker": "XNCR",
      "partner_name": "Janssen",
      "deal_type": "co_development",
      "announcement_date": "2018-04-23",
      "upfront_payment": 50,
      "total_potential_value": 500,
      "indication": "oncology",
      "asset_name": "CD28 bispecifics",
      "is_active": true
    },
    {
      "ticker": "VERA",
      "partner_name": "Eli Lilly",
      "deal_type": "acquisition_option",
      "announcement_date": "2023-07-31",
      "upfront_payment": 50,
      "total_potential_value": 600,
      "indication": "oncology",
      "asset_name": "NX-5948 BTKI",
      "is_active": true
    },
    {
      "ticker": "TGTX",
      "partner_name": "Janssen",
      "deal_type": "exclusive_license",
      "announcement_date": "2021-11-30",
      "upfront_payment": 50,
      "total_potential_value": 600,
      "indication": "oncology",
      "asset_name": "Briumvi (ex-US)",
      "is_active": true
    },
    {
      "ticker": "MIRM",
      "partner_name": "Ipsen",
      "deal_type": "exclusive_license",
      "announcement_date": "2024-08-05",
      "upfront_payment": 50,
      "total_potential_value": 800,
      "indication": "hepatology",
      "asset_name": "Livmarli (ex-US)",
      "is_active": true
    },
    {
      "ticker": "ACAD",
      "partner_name": "Takeda",
      "deal_type": "supply_agreement",
      "announcement_date": "2019-03-15",
      "upfront_payment": 0,
      "total_potential_value": 100,
      "indication": "rare disease",
      "asset_name": "Commercial agreement",
      "is_active": true
    },
    {
      "ticker": "NBIX",
      "partner_name": "Takeda",
      "deal_type": "exclusive_license",
      "announcement_date": "2023-05-02",
      "upfront_payment": 0,
      "total_potential_value": 200,
      "indication": "neurology",
      "asset_name": "Crenessity (ex-US)",
      "is_active": true
    },
    {
      "ticker": "AUTL",
      "partner_name": "Carisma Therapeutics",
      "deal_type": "research_collaboration",
      "announcement_date": "2023-09-12",
      "upfront_payment": 5,
      "total_potential_value": 50,
      "indication": "oncology",
      "asset_name": "CAR-M research",
      "is_active": true
    }
  ]
}
